

Therapeutics Advisory Group Update - Issue 22 – April 2023

All recommendations discussed at the **March** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – March 2023. Please share within your organisation as appropriate.

Commissioning Summary

<p>Formulary application - Icosapent Ethyl (Vazkepa®) with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides as per TA805</p>	<ul style="list-style-type: none"> ADVICE - initiation in primary care on advice from secondary care
<p>Commissioning Review - Palforzia for treating peanut allergy in children and young people as per TA769</p>	<ul style="list-style-type: none"> Local policy developed for use within clinics Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
<p>Formulary application - Methadone for pain relief:</p> <ul style="list-style-type: none"> Refractory neuropathic pain Severe, iatrogenic opioid dependence patients Patients with chronic pain response to doses of strong opioid 	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
<p>Formulary application – Lidocaine and Hydrocortisone mouthwash</p>	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
<p>NICE 'Highly Specialised Technologies' guidance documents</p>	<ul style="list-style-type: none"> Commissioned via NHS specialist commissioning Treatments listed in HST guidance awarded appropriate classifications as per NICE guidance Added to Netformulary and TAG recommendations document
<p>Update from previous recommendation – TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</p>	<ul style="list-style-type: none"> Abatacept amended to BLACK - Not commissioned. No NHS prescribing in primary or secondary care NICE does not consider this to be cost-effective
<p>Netformulary Updates</p>	<ul style="list-style-type: none"> Eye section is now live
<p>We have several sections live on Netformulary. If you have any formulary queries, please remember to check there first before emailing the generic inbox</p>	

Shared Care Updates

<p>Updated RMOG Shared Care Agreements</p> <ul style="list-style-type: none"> Riluzole 	<ul style="list-style-type: none"> Supported by the TAG Published on Netformulary and Knowledge Anglia
<p>Cenobamate – Shared Care Prescribing Guidance Update</p>	<ul style="list-style-type: none"> Supported by the TAG Amber 0 - Prescribe the drug and perform a basic level of monitoring

NICE Guidance – acknowledged by the TAG

CG124 – updated Jan 2023 - Hip fracture: management
NG213 – updated Jan 2023 - Disabled children and young people up to 25 with severe complex needs
NG209 – updated Jan 2023 - Tobacco: preventing uptake, promoting quitting and treating dependence
NG19 – updated Jan 2023 - Diabetic foot problems: prevention and management
CG103 – updated Jan 2023 - Delirium: prevention, diagnosis and management in hospital and long-term care
NG231 – February 2023 - Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management
CG181 – updated Feb 2023 - Cardiovascular disease: risk assessment and reduction, including lipid modification

NICE Technology Appraisals – ICB Commissioning Responsibility

TA856 – Jan 2023 - Upadacitinib (Rinvoq®) for treating moderately to severely active ulcerative colitis	BLUE - No formal application has been made for addition to the formulary. Seek advice from Medicines Optimisation Team before prescribing
TA861 – February 2023 - Upadacitinib (RINVOQ®) for treating active non-radiographic axial spondyloarthritis	
TA863 – February 2023 - Somatrogon (Ngenla®) for treating growth disturbance in children and young people aged 3 years and over	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA859 – Jan 2023 - Angiotensin II for treating vasodilator-resistant hypotension caused by septic or distributive shock (terminated appraisal)	BLACK - Not commissioned. No NHS prescribing in primary or secondary care

NICE Technology Appraisals – NHS England Commissioning Responsibility

TA855 – Jan 2023 - Mobocertinib (EXKIVITY®) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA857 – Jan 2023 - Nivolumab (Opdivo®) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	
TA858 – Jan 2023 - Lenvatinib (Kisplyx®) with pembrolizumab (Keytruda®) for untreated advanced renal cell carcinoma	
TA860 – Jan 2023 - Maribavir (Livtency®) for treating refractory cytomegalovirus infection after transplant	
TA862 – February 2023 - Trastuzumab deruxtecan (Enhertu®) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	
TA864 – February 2023 - Nintedanib (Ofev®) for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	
TA865 – February 2023 - Nivolumab (Opdivo®) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	
TA866 – February 2023 - Regorafenib (Stivarga®) for previously treated metastatic colorectal cancer	
TA868 – February 2023 - Vutrisiran (Amvuttra®) for treating hereditary transthyretin-related amyloidosis	
TA870 – February 2023 - Ixazomib (Ninlaro®) with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	
TA867 – February 2023 - Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	
TA869 – February 2023 - Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)	